i have a patient i want to start on Glow

To start a patient on Glow, you may consider the following information regarding BPC-157, which is a component of the Glow protocol: 1. **Mechanism of Action**: BPC-157 is a synthetic pentadecapeptide that has shown effects in animal studies, including promoting angiogenesis, modulating growth factor pathways, and enhancing fibroblast migration, which are associated with accelerated healing of various tissues and cytoprotective effects on the gut lining [1]. 2. **Safety and Regulatory Considerations**: The human safety data for BPC-157 are limited, and it is not an approved drug in many regions. There are concerns regarding sourcing and purity, so these factors should be considered before use [1]. 3. **Dosing Protocol**: A common dosing regimen for BPC-157 is 250 mcg subcutaneously twice daily for 4 weeks, followed by 250 mcg once daily for maintenance [5]. 4. **Monitoring**: It is recommended to monitor inflammatory markers, including hs-CRP, at baseline and every 4 weeks during treatment [5]. 5. **Combination with Other Agents**: BPC-157 is often combined with TB-500 to support connective tissue and tendon recovery [5]. Please remember that this information is for decision support only and does not constitute a treatment recommendation or dosing guidance. Always use your clinical judgment when considering treatment options.